Efficacy and safety of induction chemoimmunotherapy in older patients with unresectable stage III NSCLC: a real-world multicenter study.

ABSTRACT:

Background

The benefit of adding immunotherapy to induction chemotherapy before definitive chemoradiotherapy (CRT) in older patients with unresectable stage III non-small-cell lung cancer (NSCLC) remains unclear.

Objectives

This real-world study aimed to evaluate the efficacy and safety of induction chemoimmunotherapy followed by CRT in this patient population.

Design

A real-world multicenter study.

Methods

In this retrospective, multicenter study, we enrolled patients aged ⩾65 years with unresectable stage III NSCLC who received CRT between January 2014 and June 2024. Patients were stratified into two groups: the induction chemoimmunotherapy group (I-CRT), who received PD-1/PD-L1 inhibitors plus chemotherapy before CRT, and the control group (Non-I-CRT), who r

SUBMITTER: Du X 

PROVIDER: S-EPMC12816512 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature